CellMax Life’s blood-based cancer detecting test can detect adenomas with close to 90 percent accuracy and cancer at 95 percent accuracy.
Eric Berthiaume, MD, was named Providence, R.I.-based University Gastroenterology’s president.
Exelixis’ cabozantinib was approved for use in patients with liver cancer. The drug was already approved for thyroid and renal cancer patients.
More articles on gastronerology:
FDA expands Cabozantinib approval to include liver cancer — 4 insights
5 experts weigh in on new GI-focused practice management companies & their implications
Blood-based CRC test detects adenomas with 90% accuracy — 4 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.